NovoCure Limited
NVCR
$11.24
-$0.44-3.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.15% | -16.96% | 47.94% | -115.64% | 8.40% |
| Total Depreciation and Amortization | 6.36% | 3.58% | 91.64% | -29.41% | -14.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.37% | 19.95% | -55.21% | 118.26% | -8.10% |
| Change in Net Operating Assets | 542.26% | 75.87% | -697.01% | -69.54% | 347.94% |
| Cash from Operations | 229.10% | 55.32% | -933.47% | -133.26% | 703.26% |
| Capital Expenditure | -3.08% | 48.30% | -18.66% | 16.30% | 6.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.89% | 901.98% | 131.19% | -163.56% | 105.75% |
| Cash from Investing | 98.51% | 656.03% | 70.86% | -317.90% | 102.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -77.46% | -54.51% | 95.42% | 2,585.00% | -96.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,111.02% | -54.51% | 95.42% | 2,585.00% | -99.89% |
| Foreign Exchange rate Adjustments | -108.30% | 16.74% | 277.34% | -247.13% | 212.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 747.96% | 161.92% | -58.68% | -211.32% | 107.18% |